Nubeqa is one of Bayer's top drugs and a potential label expansion should further boost sales. The drug generated sales of more than €1 billion in the first nine months of 2024.

The data will be filed with regulatory authorities to seek an expansion of the label for Nubeqa, according to Bayer, which developed Nubeqa in collaboration with Finland's Orion. The drug is ...

Bayer initiates phase II panSOHO study with BAY 2927088 in metastatic or unresectable HER2 mutant solid tumours: Berlin Wednesday, March 5, 2025, 09:00 Hrs [IST] Bayer announced t ...

First patient enrolled in the Phase II panSOHO basket trial; this is the third BAY 2927088 clinical trial in patients with HER2- activating mutations ...